At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 123 enrolled
Drug / intervention
Imsidolimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
In Brief
A Phase 2 clinical trial evaluating Imsidolimab and Placebo for Acne Vulgaris. Completed, enrolled 123 participants across 15 sites in 2 countries.
Detailed Summary
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionFeb 2022
Study CompletionMar 2022
TodayJul 2026
First PostedApr 23, 2021
Enrollment StartMay 15, 2021
Primary CompletionFeb 1, 2022
Study CompletionMar 29, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.2 years ago
Interventions
Imsidolimabdrug
Humanized Monoclonal Antibody
Placebobiological
Placebo